Europe Cell and Gene Therapy Market
The Europe cell and gene therapy market was valued at US$ 1,105.10 million in 2023 and is projected to reach US$ 5,334.44 million by 2031; it is estimated to record a CAGR of 21.7% from 2023 to 2031. Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing Drives Europe Cell and Gene Therapy Market
Cell and gene therapy manufacturing is a complex process, which makes the proper execution and monitoring of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual and open manufacturing method, as well as building a more commercially suitable process, can be challenging. Therefore, these manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs support product development, manufacturing, clinical trials, and commercialization services to cell and gene therapy companies on a contract basis. Under the partnership with a CDMO, cell and gene therapy manufacturers support scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. Outsourcing cell and gene therapy manufacturing to CDMOs proves to be cost-effective for manufacturers. They gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the Europe cell and gene therapy market growth.Europe Cell and Gene Therapy Market Overview
The cell and gene therapy market in Germany is expected to witness significant growth during the forecast period due to factors such as investment in the setup of production capacity, high government support, and involvement in the region. Also, the presence of top competitive players will enhance the regional market growth during the forecast period. Germany has a strong pharmaceutical industry with a notable focus on R&D. The country has 660 biotechnology companies that employ 50,000 employees. Among these, 660 companies are focused on cell and gene therapies (CGTs). As per the NecstGen report, more than 29 active clinical trials evaluating CAR-modified immune cells were ongoing in 2023, and most of the production involved CAR-T cells. Also, over 50 clinical studies have been conducted in gene therapy in Germany so far. The innovation efforts of German CGT companies are majorly focused on the local or country level, as they lack international presence.
Europe Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)
Strategic insights for the Europe Cell and Gene Therapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Cell and Gene Therapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Europe Cell and Gene Therapy Strategic Insights
Get more information on this report Europe Cell and Gene Therapy Report Scope
Report Attribute
Details
Market size in 2023
US$ 1,105.10 Million
Market Size by 2031
US$ 5,334.44 Million
Global CAGR (2023 - 2031)
21.7%
Historical Data
2025-2031
Forecast period
2021-2023
Segments Covered
By Type
By Services
By Scale
By Service Providers
Regions and Countries Covered
Europe
Market leaders and key company profiles
Get more information on this report Europe Cell and Gene Therapy Regional Insights
Get more information on this report
Europe Cell and Gene Therapy Market Segmentation
The Europe cell and gene therapy market is categorized into type, services, scale, end user, and country.
Based on type, the Europe cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.
In terms of services, the Europe cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.
By scale, the Europe cell and gene therapy market is bifurcated into pre commercial/ R and D manufacturing and commercial scale manufacturing. The pre commercial/ R and D manufacturing segment held a larger market share in 2023.
Based on end user, the Europe cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.
By country, the Europe cell and gene therapy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe cell and gene therapy market share in 2023.
Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Europe cell and gene therapy market.
The Europe Cell and Gene Therapy Market is valued at US$ 1,105.10 Million in 2023, it is projected to reach US$ 5,334.44 Million by 2031.
As per our report Europe Cell and Gene Therapy Market, the market size is valued at US$ 1,105.10 Million in 2023, projecting it to reach US$ 5,334.44 Million by 2031. This translates to a CAGR of approximately 21.7% during the forecast period.
The Europe Cell and Gene Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Cell and Gene Therapy Market report:
The Europe Cell and Gene Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Cell and Gene Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Cell and Gene Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Cell and Gene Therapy Market
